Letter to Editor

Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”

Volume: 19 Number: 3 July 10, 2026
EN TR

Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”

Abstract

Asthma-COPD overlap (ACO) is a controversial concept without a universally accepted definition. In the study by Aslan and Enli, ACO was defined based on airflow limitation and reversibility; however, this approach may not fully reflect current guideline perspectives. Recent GINA and GOLD reports emphasize a phenotype-based approach rather than defining ACO as a distinct disease entity. Therefore, the observed limited diagnostic value of prostaglandin D2 (PGD2) may be influenced by methodological limitations, particularly patient selection and classification strategy.

 

 

 

Keywords

References

  1. Aslan SH, Enli Y. The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis. Pam Med J. 2026;19:413-422.
  2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2022.
  3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2022.
  4. Awad MT, Sankari A. Asthma and COPD overlap. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
  5. Uzan GC, Borekci S, Doventas YE, Koldas M, Gemicioglu B. The relationship between inflammatory markers and spirometric parameters in ACOS, asthma, and COPD. J Asthma. 2020;57(12):1273-1279.
  6. Özdemir F. KOAH tanılı hastalarda astım-KOAH overlap sıklığı ve prostaglandin D2’nin tanısal değeri. Tıpta Uzmanlık Tezi, 2021.

Details

Primary Language

English

Subjects

Chest Diseases

Journal Section

Letter to Editor

Publication Date

July 10, 2026

Submission Date

May 11, 2026

Acceptance Date

July 7, 2026

Published in Issue

Year 2026 Volume: 19 Number: 3

APA
Atlı, S. (2026). Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”. Pamukkale Medical Journal, 19(3), 219-220. https://doi.org/10.31362/patd.1948929
AMA
1.Atlı S. Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis.” Pam Med J. 2026;19(3):219-220. doi:10.31362/patd.1948929
Chicago
Atlı, Siahmet. 2026. “Comment On: ‘The Prevalence of Asthma-COPD Overlap (ACO) Among COPD Patients and the Role of Prostaglandin D2 (PGD2) in Differential Diagnosis’”. Pamukkale Medical Journal 19 (3): 219-20. https://doi.org/10.31362/patd.1948929.
EndNote
Atlı S (July 1, 2026) Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”. Pamukkale Medical Journal 19 3 219–220.
IEEE
[1]S. Atlı, “Comment on: ‘The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis’”, Pam Med J, vol. 19, no. 3, pp. 219–220, July 2026, doi: 10.31362/patd.1948929.
ISNAD
Atlı, Siahmet. “Comment On: ‘The Prevalence of Asthma-COPD Overlap (ACO) Among COPD Patients and the Role of Prostaglandin D2 (PGD2) in Differential Diagnosis’”. Pamukkale Medical Journal 19/3 (July 1, 2026): 219-220. https://doi.org/10.31362/patd.1948929.
JAMA
1.Atlı S. Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”. Pam Med J. 2026;19:219–220.
MLA
Atlı, Siahmet. “Comment On: ‘The Prevalence of Asthma-COPD Overlap (ACO) Among COPD Patients and the Role of Prostaglandin D2 (PGD2) in Differential Diagnosis’”. Pamukkale Medical Journal, vol. 19, no. 3, July 2026, pp. 219-20, doi:10.31362/patd.1948929.
Vancouver
1.Siahmet Atlı. Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”. Pam Med J. 2026 Jul. 1;19(3):219-20. doi:10.31362/patd.1948929

Creative Commons Lisansı

Pamukkale Medical Journal is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC).